Alpha Cognition Inc. ( ACOG) Discusses Commercial Adoption Metrics and Market Opportunity in Long-Term Care December 2, 2025 12:00 PM EST ...
Walk down any health aisle (or scroll through your favorite wellness influencer’s page), and it’s clear: the supplement ...
The Alzheimer’s drugs market is projected to grow at a compound annual growth rate (CAGR) of approximately 20% during the ...
GLP-1 medicines cause malnutrition in 22% of patients. Multivitamins are often inadequate. Patients need dietitian support ...
The tests have not been approved by federal regulators, but that hasn’t stopped patients from wanting them — and doctors from worrying.
Merck granted Fast Track Designation by the U.S. FDA for MK-2214 for the treatment of Alzheimer's diseaseRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and ...
If you have a Good Question you’d like us to try to answer, send it to [email protected]. If you have a Good Question you’d like us to try to answer, send it to [email protected]. If you have ...
News-Medical.Net on MSN
First new fibromyalgia drug in 15 years, Tonmya (cyclobenzaprine HCl) gains FDA approval and hits pharmacy shelves
In a milestone moment for chronic pain management, Tonix Pharmaceuticals announced on August 15, 2025, that its novel ...
GLP-1 drugs like, Ozempic and Wegovy, are in big demand... And they’re going to be more affordable. Two physicians answer the questions we still have about GLP-1s.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback